Drug Profile
Research programme: human amniocyte-derived protein therapeutics - CEVEC Pharmaceuticals
Alternative Names: C1Inh; CPr1; CPr2; CPr3; CPr4; Recombinant human alpha-1-antitrypsin; Recombinant human C1 esterase inhibitor - CEVEC; rhAAT - CEVEC; rhC1-INH - CEVECLatest Information Update: 10 Oct 2022
Price :
$50
*
At a glance
- Originator CEVEC Pharmaceuticals
- Class Glycoproteins; Proteins
- Mechanism of Action Complement C1 inhibitors; Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alpha 1-antitrypsin deficiency; Hereditary angioedema; Unspecified
Most Recent Events
- 06 Oct 2022 CEVEC Pharmaceuticals has been acquired by Cytiva
- 28 May 2020 No recent reports of development identified for preclinical development in Hereditary-angioedema in Germany (Parenteral)
- 28 Feb 2018 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in Germany (Parenteral)